Redeye sees an excellent Q2-report, where all segments vastly outperformed our EBITA* forecasts. The margin was boosted by cost cuts and solid demand in scalable businesses. Organic growth was -2% and the business model has surely proven itself. We will most likely raise our forecasts and Base case. However, the share price has increased significantly, and we will get back to our updated view on the share in our Q2 update.
All three segments far better than expected – group EBITA* 95% above forecast
High margin due to a mix of sustainable and unsustainable cost reductions
SEK 5.7m in government support on the group level
Expect to catch up delayed orders in 2020 and 2021
Raised margin guidance for SIS regarding 2020 to 22-25% (20-22)
The target of 5-10% organic EBITA* growth in 2020 remains – now seems reasonable given strong H1
We will most likely increase our forecasts and Base case
Fredrik Nilsson
Equity Analyst
Tagged companies
You need to be a Redeye member to access this content
Become a member to:
Access all our extensive research on 100+ Nordic Tech and Life Science companies
Make smarter investment decisions with the guidance of our experienced analysts
Receive exciting offers to participate in IPO’s and other transactions
By clicking "Sign up" you indicate that you read and agree to our Terms & Conditions